- Home
- FCBC vs JANX Comparison
FCBC vs JANX Comparison
Compare FCBC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCBC | JANX |
|---|---|---|
| Founded | 1874 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.5M | 790.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FCBC | JANX |
|---|---|---|
| Price | $43.20 | $14.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | 70.5K | ★ 961.6K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | $16.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.21 | $12.12 |
| 52 Week High | $43.49 | $35.34 |
Technical Indicators
Market Signals| Indicator | FCBC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 69.35 | 60.70 |
| Support Level | $38.60 | $13.10 |
| Resistance Level | N/A | $15.49 |
| Average True Range (ATR) | 0.98 | 0.54 |
| MACD | 0.13 | 0.10 |
| Stochastic Oscillator | 90.36 | 79.25 |
Price Performance
Historical ComparisonAbout FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.